The U.S. National Institutes of Health is ending a key pathway for early-career clinician-scientists: K career-development awards will no longer fund clinical trials, the agency announced this week.
The change, detailed in a policy notice (NOT-OD-26-098), means NIH will no longer support "Independent Clinical Trial Required" K award funding opportunities, and K award funds may not be used to support the conduct of clinical trials. The move takes effect in July 2027, giving current and prospective recipients time to adjust.
K awards are a cornerstone of the biomedical research workforce, helping roughly 90 researchers a year — typically physicians and PhDs in the early stages of their careers — transition from mentored training to independent research. For clinician-scientists, the awards have long been the bridge between seeing patients and running trials designed to answer the questions those patients raise.
NIH frames the decision as simplification: the agency says it is streamlining the career development landscape, which currently includes multiple K mechanisms with overlapping rules, and it has invited feedback from the community before finalizing the structure.
But researchers in academic medicine worry about what is lost. Clinical trial experience is expensive and difficult to fund through traditional R01-style grants, and removing trials from K awards could push budding clinical researchers toward laboratory work — or out of the pipeline altogether — at a time when the U.S. faces a well-documented shortage of physician-scientists.
Critics also point to context: the change arrives amid broader NIH restructuring, grant terminations and budget pressures that have already disrupted clinical research sites across the country. For those who study the biomedical workforce, the question is whether the simplification will make career paths clearer — or narrower.
The agency says recipients can still conduct clinical trials through other mechanisms, and that the goal is a simpler, more predictable set of awards. Whether the result is a stronger pipeline of clinician-scientists is a question that will only be answered in the decade ahead, when today's early-career researchers either are — or are not — running the trials of the future.
